Boston Scientific Corporation $BSX Shares Purchased by Welch Group LLC

Welch Group LLC boosted its position in Boston Scientific Corporation (NYSE:BSX) by 3.5% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 4,641 shares of the medical equipment provider’s stock after purchasing an additional 159 shares during the quarter. Welch Group LLC’s holdings in Boston Scientific were worth $498,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of BSX. 1248 Management LLC acquired a new position in shares of Boston Scientific in the first quarter valued at approximately $26,000. Y.D. More Investments Ltd acquired a new position in Boston Scientific in the 1st quarter valued at $27,000. Sound Income Strategies LLC raised its holdings in Boston Scientific by 90.9% in the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 120 shares during the last quarter. Oliver Lagore Vanvalin Investment Group acquired a new position in Boston Scientific in the second quarter valued at $37,000. Finally, Activest Wealth Management increased its stake in Boston Scientific by 6,216.7% in the first quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider’s stock valued at $38,000 after purchasing an additional 373 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Stock Down 1.9%

Shares of Boston Scientific stock opened at $95.41 on Monday. The business has a 50-day moving average of $101.98 and a 200-day moving average of $101.87. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The company has a market capitalization of $141.38 billion, a PE ratio of 56.79, a P/E/G ratio of 2.30 and a beta of 0.61. Boston Scientific Corporation has a 1-year low of $80.64 and a 1-year high of $109.50.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The company had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same period last year, the firm earned $0.62 earnings per share. The company’s revenue was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, equities analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

BSX has been the subject of several analyst reports. Needham & Company LLC reiterated a “buy” rating and issued a $121.00 target price on shares of Boston Scientific in a research note on Wednesday, October 1st. Oppenheimer raised shares of Boston Scientific from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $118.00 to $125.00 in a research note on Monday, September 8th. Jefferies Financial Group reaffirmed a “hold” rating on shares of Boston Scientific in a research report on Monday, July 21st. Wells Fargo & Company upped their price target on shares of Boston Scientific from $118.00 to $124.00 and gave the stock an “overweight” rating in a research report on Thursday, July 24th. Finally, Leerink Partners upped their price target on shares of Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 1st. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, Boston Scientific has a consensus rating of “Buy” and an average target price of $120.71.

Insiders Place Their Bets

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business’s stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $98.47, for a total value of $4,923,500.00. Following the completion of the sale, the executive vice president owned 178,342 shares of the company’s stock, valued at approximately $17,561,336.74. The trade was a 21.90% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the completion of the sale, the executive vice president directly owned 23,600 shares of the company’s stock, valued at $2,469,268. The trade was a 42.32% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 174,214 shares of company stock valued at $17,972,457 over the last 90 days. 0.50% of the stock is owned by company insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.